Helen Torley I.'s Insider Trades & SAST Disclosures
Helen Torley I.'s most recent trade in Halozyme Therapeutics Inc. was a trade of 22,436 Restricted Stock Units done . Disclosure was reported to the exchange on Feb. 23, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Helen Torley I..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 22,436 | 67,308 | - | - | Restricted Stock Units | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 22,436 | 745,800 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.75 per share. | 23 Feb 2025 | 12,081 | 733,719 (0%) | 0% | 57.8 | 697,678 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 71,038 | 71,038 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 67,027 | 67,027 | - | - | Restricted Stock Units | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 71,810 | 0 | - | - | Performance Stock Units | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 71,810 | 744,548 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 38,668 | 705,880 (0%) | 0% | 58.3 | 2,253,958 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 21,009 | 21,009 | - | - | Restricted Stock Units | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 21,009 | 726,889 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 16,875 | 33,749 | - | - | Restricted Stock Units | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 16,875 | 732,451 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 13,092 | 0 | - | - | Restricted Stock Units | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 13,092 | 679,836 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 11,313 | 715,576 (0%) | 0% | 58.3 | 659,435 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 9,087 | 723,364 (0%) | 0% | 58.3 | 529,681 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 7,098 | 672,738 (0%) | 0% | 58.3 | 413,742 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 96,155 | 96,155 | - | - | Performance Stock Units | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 24,957 | 71,810 | - | - | Performance Stock Units | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 23,260 | 23,260 | - | - | Performance Stock Unit | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 20,008 | 31,364 | - | - | Performance Stock Units | |
|
Halozyme Therapeutics Inc.
|
I. Torley Helen | Director, PRESIDENT AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Nov 2024 | 10,000 | 666,744 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 08 Oct 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 10,000 | 0 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 10,000 | 10,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 08 Oct 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 53.94 per share. | 08 Oct 2024 | 9,100 | 677,644 (0%) | 0% | 53.9 | 490,845 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 51.85 per share. | 08 Oct 2024 | 5,981 | 680,763 (0%) | 0% | 51.8 | 310,097 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 53.91 per share. | 08 Oct 2024 | 2,404 | 676,744 (0%) | 0% | 53.9 | 129,590 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 53.31 per share. | 08 Oct 2024 | 1,615 | 679,148 (0%) | 0% | 53.3 | 86,096 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 54.57 per share. | 08 Oct 2024 | 900 | 676,744 (0%) | 0% | 54.6 | 49,116 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 24 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2024 | 10,000 | 20,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2024 | 10,000 | 30,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2024 | 10,000 | 40,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.10 per share. | 24 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 56.1 | 560,970 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 24 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.34 per share. | 24 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 56.3 | 563,370 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 24 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 58.21 per share. | 24 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 58.2 | 582,100 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 10 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 59.20 per share. | 10 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 59.2 | 592,030 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,000 | 60,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 10 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,000 | 50,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,000 | 70,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 59.09 per share. | 10 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 59.1 | 590,870 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 10 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 59.09 per share. | 10 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 59.1 | 590,890 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 13 Aug 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 10,000 | 80,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 10,000 | 90,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 10,000 | 100,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 57.95 per share. | 13 Aug 2024 | 10,000 | 676,744 (0%) | 0% | 57.9 | 579,490 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 13 Aug 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 13 Aug 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.25 per share. | 13 Aug 2024 | 10,000 | 676,744 (0%) | 0% | 56.2 | 562,490 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 57.73 per share. | 13 Aug 2024 | 6,537 | 676,944 (0%) | 0% | 57.7 | 377,394 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.22 per share. | 13 Aug 2024 | 3,263 | 683,481 (0%) | 0% | 56.2 | 183,443 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 58.17 per share. | 13 Aug 2024 | 200 | 676,744 (0%) | 0% | 58.2 | 11,634 | Common Stock |
|
Halozyme Therapeutics Inc.
|
I. Helen Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 93,002 | 93,002 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen Torley I. | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 89,744 | 89,744 | - | - | Restricted Stock Units | |
|
Halozyme Therapeutics Inc.
|
Torley I. Helen | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 21,009 | 680,231 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
Torley I. Helen | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 21,009 | 42,018 | - | - | Restricted Stock Units | |
|
Halozyme Therapeutics Inc.
|
I. Torley Helen | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 16,875 | 685,814 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
I. Torley Helen | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 16,875 | 50,624 | - | - | Restricted Stock Units | |
|
Halozyme Therapeutics Inc.
|
Helen Torley I. | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.10 per share. | 16 Feb 2024 | 11,292 | 668,939 (0%) | 0% | 36.1 | 407,641 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.10 per share. | 16 Feb 2024 | 9,070 | 676,744 (0%) | 0% | 36.1 | 327,427 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 32,781 | 676,841 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
I. Torley Helen | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.91 per share. | 15 Feb 2024 | 17,619 | 659,222 (0%) | 0% | 35.9 | 632,698 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Torley I. Helen | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 13,092 | 651,096 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 13,092 | 13,092 | - | - | Restricted Stock Units | |
|
Halozyme Therapeutics Inc.
|
Helen Torley I. | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.91 per share. | 15 Feb 2024 | 7,036 | 644,060 (0%) | 0% | 35.9 | 252,663 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Torley Helen I. | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 31,281 | 0 | - | - | Restricted Stock Units | |
|
Halozyme Therapeutics Inc.
|
Torley I. Helen | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 31,281 | 654,947 (0%) | 0% | 0 | Common Stock | |
|
Halozyme Therapeutics Inc.
|
I. Torley Helen | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.49 per share. | 10 Feb 2024 | 16,943 | 638,004 (0%) | 0% | 35.5 | 601,307 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 29 Aug 2023 | 10,000 | 633,666 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2023 | 10,000 | 110,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2023 | 10,000 | 120,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2023 | 10,000 | 130,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 42.82 per share. | 29 Aug 2023 | 10,000 | 623,666 (0%) | 0% | 42.8 | 428,170 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 29 Aug 2023 | 10,000 | 633,666 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 42.85 per share. | 29 Aug 2023 | 10,000 | 623,666 (0%) | 0% | 42.9 | 428,540 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 29 Aug 2023 | 10,000 | 633,666 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 42.40 per share. | 29 Aug 2023 | 10,000 | 623,666 (0%) | 0% | 42.4 | 424,020 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 43.77 per share. | 15 Aug 2023 | 10,000 | 623,666 (0%) | 0% | 43.8 | 437,680 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 10,000 | 140,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 10,000 | 150,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 10,000 | 160,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 43.18 per share. | 15 Aug 2023 | 10,000 | 623,666 (0%) | 0% | 43.2 | 431,820 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 15 Aug 2023 | 10,000 | 633,666 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 43.53 per share. | 15 Aug 2023 | 10,000 | 623,666 (0%) | 0% | 43.5 | 435,320 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 15 Aug 2023 | 10,000 | 633,666 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 15 Aug 2023 | 10,000 | 633,666 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 42.69 per share. | 25 Jul 2023 | 10,000 | 623,666 (0%) | 0% | 42.7 | 426,890 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 10,000 | 170,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 10,000 | 180,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 10,000 | 190,000 | - | - | Option to Purchase Common Stock | |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 43.79 per share. | 25 Jul 2023 | 10,000 | 623,666 (0%) | 0% | 43.8 | 437,900 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 25 Jul 2023 | 10,000 | 633,666 (0%) | 0% | 13.9 | 138,700 | Common Stock |
|
Halozyme Therapeutics Inc.
|
Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 25 Jul 2023 | 10,000 | 633,666 (0%) | 0% | 13.9 | 138,700 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges